CN103675262A - Method of stable fluorescence labeling of living cells of oral squamous cell carcinoma - Google Patents
Method of stable fluorescence labeling of living cells of oral squamous cell carcinoma Download PDFInfo
- Publication number
- CN103675262A CN103675262A CN201310741811.2A CN201310741811A CN103675262A CN 103675262 A CN103675262 A CN 103675262A CN 201310741811 A CN201310741811 A CN 201310741811A CN 103675262 A CN103675262 A CN 103675262A
- Authority
- CN
- China
- Prior art keywords
- squamous cell
- living cells
- oral squamous
- cell carcinomas
- fluorescence labeling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/18—Dental and oral disorders
Abstract
The invention discloses a method of stable fluorescence labeling of living cells of oral squamous cell carcinoma. The method is capable of labelling the living cells of the oral squamous cell carcinoma by utilizing fluorescence coupled Nimotuzumab. According to the method, the living cells of the oral squamous cell carcinoma are stably labelled, so that the living cells of the oral squamous cell carcinoma are observed and researched, the experiment measures of researchers are enriched, and the corresponding research fields are expanded.
Description
Technical field
The invention belongs to tumour molecular image technical field, be specifically related to a kind of method of stable fluorescence labeling oral squamous cell carcinomas living cells.
Background technology
OSCC (Oral squmaous cell carcinoma, OSCC) be called for short oral squamous cell carcinomas, for mainly betiding the malignant tumour at the positions such as oral mucous epithelia, it is the common malignant tumour of incidence, account for the 90%-95% of oral and maxillofacial malignancy, often cause serious oral and maxillofacial surgery deformity and chew, swallow with the dysfunction such as language and threaten patient's life.Secondly the site of pathological change of oral squamous cell carcinomas is maximum with tongue, take gum as many, in addition, buccal mucosa, palate, mouthful end etc. other oral mucosa and jawbone, salivary gland on also have generation.
In prior art, the fluorescence labeling of oral cavity squamous cell carcinoma cell is mainly the dead cell adopting after fixing, although complete through fixing cellular morphology, imaging effect is good, but the oral cavity squamous cell carcinoma of having no idea cell living cells carries out stable mark, thereby cannot carry out the observational study of oral squamous cell carcinomas living cells.
Summary of the invention
The object of the invention is to overcome prior art defect, a kind of method of stable fluorescence labeling oral squamous cell carcinomas living cells is provided.
Technical scheme of the present invention is as follows:
A method for stable fluorescence labeling oral squamous cell carcinomas living cells, carries out mark with the appropriate pearl monoclonal antibody of the Buddhist nun oral cavity squamous cell carcinoma living cells of fluorescence coupling.
In a preferred embodiment of the invention, the appropriate pearl monoclonal antibody of the Buddhist nun of described fluorescence coupling fluorescent material used is near-infrared fluorescent materials A lexa680.
Further preferred, comprise the steps:
(1) by near-infrared fluorescent materials A lexa680 and the coupling of the appropriate pearl monoclonal antibody of Buddhist nun;
(2) by the appropriate pearl monoclonal antibody of the Buddhist nun of Alexa680 coupling and oral squamous cell carcinomas living cells carry out lucifuge and hatch rear washing;
(3) carrying out flow cytometer detection and Laser Scanning Confocal Microscope detects.
Further preferred, the excitation wavelength that described flow cytometer detects is 633nm, transmitting filter disc 670LP.
Further preferred, the excitation wavelength that described Laser Scanning Confocal Microscope detects is 633nm, transmitting filter disc 650LP.
In a preferred embodiment of the invention, the appropriate pearl monoclonal antibody of the Buddhist nun of described fluorescence coupling fluorescent material used is quantum dot Qdot800.
Further preferred, comprise the steps:
(1) by quantum dot Qdot800 and the coupling of the appropriate pearl monoclonal antibody of Buddhist nun;
(2) the appropriate pearl monoclonal antibody of the Buddhist nun of Qdot800 coupling and oral squamous cell carcinomas living cells are carried out to lucifuge and hatch rear washing;
(3) carrying out flow cytometer detection and Laser Scanning Confocal Microscope detects.
Further preferred, the excitation wavelength that described flow cytometer detects is 407nm, transmitting filter disc 780/60nm.
Further preferred, the excitation wavelength that described Laser Scanning Confocal Microscope detects is 488nm, transmitting filter disc 650LP.
The invention has the beneficial effects as follows:
1, method of the present invention is carried out stable labelling with the appropriate pearl monoclonal antibody of the Buddhist nun oral cavity squamous cell carcinoma living cells of fluorescence coupling, thereby can carry out the observational study of oral squamous cell carcinomas living cells, has enriched researchist's laboratory facilities, has expanded corresponding research field;
2, employing near-infrared fluorescent materials A lexa680 of the present invention and quantum dot Qdot800 carry out coupling as fluorescence labeling material and the appropriate pearl of oral squamous cell carcinomas monoclonal antibody specific Buddhist nun, and fluorescence intensity is high, mark high specificity, and imaging is stable and the holding time is long;
3, method of the present invention is easy and simple to handle fast, and with low cost.
4, appropriate pearl monoclonal antibody (Nimotuzumab, h-R of Buddhist nun
3, trade name Tai Xinsheng) and be a kind of human monocloned antibody against EGFR molecular targeted agents of new clinical practice, this method can be used for mark, and other crosses the cell of expressing EGFR.
Accompanying drawing explanation
Fig. 1 is one of Laser Scanning Confocal Microscope photo of the embodiment of the present invention 2 (400 *);
Fig. 2 is two (1000 *) of the Laser Scanning Confocal Microscope photo of the embodiment of the present invention 2;
Fig. 3 is the Laser Scanning Confocal Microscope photo (1000 *) of the embodiment of the present invention 4.
Embodiment
By embodiment, by reference to the accompanying drawings technical scheme of the present invention is further detailed and is described below.
Embodiment 1
(1) press product description operation, by near-infrared fluorescent materials A lexa680(invitrogen company) and the appropriate pearl monoclonal antibody of Buddhist nun (Bai Tai company) coupling, prepare the appropriate pearl monoclonal antibody of fluorescently-labeled Buddhist nun probe (Alexa680 – Nim);
(2) after the oral squamous cell carcinomas CAL27 cell dissociation of taking the logarithm growth period, under inverted phase contrast microscope, count, the centrifugal supernatant of abandoning, adds PBS to adjust cell density to 2 * 10
6/ mL, then divides cell suspension to streaming dedicated pipe, 100 μ L/ pipes.
(3) add Alexa680 – Nim, making its final concentration in PBS is 25 μ g/mL, and 4 ℃ of lucifuges are hatched half an hour.
(3) labelling experiment: minute experimental group and control group
Experimental group: add Alexa680 – Nim, making its final concentration in PBS is 25 μ g/mL, and 4 ℃ of lucifuges are hatched half an hour;
Control group: comprise following four groups, all the other processing and incubation conditions are identical with experimental group
1. PBS blank
2. with Alexa680, replace Alexa680 – Nim, concentration 25 μ g/mL
3. first cell is hatched half an hour at 4 ℃ with the PBS100 μ L containing Buddhist nun's trastuzumab 1uL, PBS washing 1 time, then add the PBS100 μ L containing Alexa680 – Nim, concentration 25 μ g/mL
4. mice skeletal sarcoblast is that C2C12 adds Alexa680 – Nim, concentration 25 μ g/mL;
(4) above-mentioned each group is used respectively to PBS washed cell 2 times, centrifugal 5 minutes of 1300rpm, is resuspended in 500 μ L PBS.
(5) Beckman flow cytometer detects, excitation wavelength 633nm, transmitting filter disc 670LP, software kit carries out interpretation of result, result is presented under the low concentration of 25 μ g/mL, Alexa680-Nim can reach very high mark rate (﹥ 98%) to CAL27 cell, and control group does not all detect obvious fluorescence.The mark specificity that shows Alexa680-Nim oral cavity squamous cell carcinoma cell CAL27 cell is very strong, and mark rate is very high.
Embodiment 2
(1) press product description operation, by near-infrared fluorescent materials A lexa680 and the coupling of the appropriate pearl monoclonal antibody of Buddhist nun, prepare the appropriate pearl monoclonal antibody of fluorescently-labeled Buddhist nun probe (Alexa680 – Nim);
(2) after well-grown CAL27 cell dissociation, go down to posterity in double dish at the bottom of the glass of diameter 35mm, central glass underfill aperture 10mm, after 2-3 days, Growth of Cells is to 70-80%.
(3) mark is first 12 hours, and stand-by cell culture fluid is changed to serum-free medium, sucks gently nutrient culture media before mark, PBS washing 2 times.
(4) in central glass bottom outlet, add the serum free medium 50uL containing Alexa680-Nim, concentration 100 μ g/mL, 4 ℃ of lucifuges are hatched half an hour.
(5) take out cell, suck liquid, PBS washing 3 times, adds a small amount of PBS, under Laser Scanning Confocal Microscope, observes.
(6) Laser Scanning Confocal Microscope observation condition: excitation wavelength 633nm, transmitting filter disc 650LP.Result as depicted in figs. 1 and 2, can detect fluorescence localization and mainly be positioned on after birth, has minute quantity fluorescence in endochylema, in karyon, does not have, consistent with EGFR expressive site.The same operation of control group does not all detect obvious fluorescence (control group designs with embodiment 1).Show the EGFR that Buddhist nun's trastuzumab fluorescence probe of Alexa680-Nim mark can specific mark CAL27 cellular expression, specificity is very strong, and mark rate is very high.
Embodiment 3
(1) press product description operation, by quantum dot Qdot800(invitrogen company) and the appropriate pearl monoclonal antibody of Buddhist nun (Bai Tai company) coupling, prepare the appropriate pearl monoclonal antibody of fluorescence quantum Buddhist nun probe (Qdot800 – Nim);
(2) after the oral squamous cell carcinomas CAL27 cell dissociation of taking the logarithm growth period, under inverted phase contrast microscope, count, the centrifugal supernatant of abandoning, adds PBS to adjust cell density to 2 * 10
6/ mL, then divides cell suspension to streaming dedicated pipe, and 100 μ L/ pipes, add respectively the experiment reagent of different amounts to streaming pipe by following design;
(3) labelling experiment: minute experimental group and control group
Experimental group: add Qdot800 – Nim, making its final concentration in PBS is 20nmol/L, and 4 ℃ of lucifuges are hatched half an hour;
Control group: comprise following four groups, all the other processing and incubation conditions are identical with experimental group.
1. PBS blank
2. with Qdot800, replace Qdot800 – Nim, concentration 20nmol/L
3. first cell is hatched half an hour at 4 ℃ with the PBS100 μ L containing Buddhist nun's trastuzumab 1uL, PBS washing 1 time, then add the PBS100 μ L containing Qdot800 – Nim, concentration 20nmol/L
4. mice skeletal sarcoblast is that C2C12 adds Qdot800 – Nim, concentration 20nmol/L;
(4) above-mentioned each group is used respectively to PBS washed cell 2 times, centrifugal 5 minutes of 1300rpm, is resuspended in 500 μ L PBS;
(5) machine testing on BD flow cytometer, excitation wavelength 407nm, transmitting filter disc 780/60nm, software kit carries out interpretation of result.Result shows: under the low concentration of 20nmol/L, Qdot800 – Nim can reach very high mark rate (﹥ 99%) to CAL27 cell, fluorescence is strong, control group can not detect fluorescence, the mark specificity that shows Qdot800 – Nim oral cavity squamous cell carcinoma cell CAL27 cell is very strong, and mark rate is very high.
Embodiment 4
(1) press product description operation, by quantum dot Qdot800(invitrogen company) and the appropriate pearl monoclonal antibody of Buddhist nun (Bai Tai company) coupling, prepare the appropriate pearl monoclonal antibody of fluorescence quantum Buddhist nun probe (Qdot800 – Nim);
(2) after well-grown CAL27 cell dissociation, go down to posterity in double dish at the bottom of the glass of diameter 35mm, central glass underfill aperture 10mm, after 2-3 days, Growth of Cells is to 70-80%.
(3) mark is first 12 hours, and stand-by cell culture fluid is changed to serum-free medium, sucks gently nutrient culture media before mark, PBS washing 2 times.
(4) in central glass bottom outlet, add the serum free medium 50uL containing Qdot800 – Nim, concentration 100nmol/L, 4 ℃ of lucifuges are hatched half an hour.
(5) take out cell, suck liquid, PBS washing 3 times, adds a small amount of PBS, under Laser Scanning Confocal Microscope, observes.
(6) Laser Scanning Confocal Microscope observation condition: excitation wavelength 488nm, transmitting filter disc 650LP.As shown in Figure 3, the fluorescence institute mark that the EGFR expressing in CAL27 cell membrane, endochylema is become clear presents result.The non-specific adsorption of quantum dot is very low, and control group does not almost observe fluorescence (control group designs with embodiment 3).The results show, the EGFR that Buddhist nun's trastuzumab fluorescence probe of Qdot800 mark can specific mark CAL27 cellular expression, mark is effective.
The above, be only preferred embodiment of the present invention, therefore can not limit according to this scope of the invention process, the equivalence done according to the scope of the claims of the present invention and description changes and modifies, and all should still belong in the scope that the present invention contains.
Claims (9)
1. a method for stable fluorescence labeling oral squamous cell carcinomas living cells, is characterized in that: with the appropriate pearl monoclonal antibody of the Buddhist nun oral cavity squamous cell carcinoma living cells of fluorescence coupling, carry out mark.
2. the method for a kind of stable fluorescence labeling oral squamous cell carcinomas living cells as claimed in claim 1, is characterized in that: the appropriate pearl monoclonal antibody of the Buddhist nun fluorescent material used of described fluorescence coupling is near-infrared fluorescent materials A lexa680.
3. the method for a kind of stable fluorescence labeling oral squamous cell carcinomas living cells as claimed in claim 2, is characterized in that: comprise the steps:
(1) by near-infrared fluorescent materials A lexa680 and the coupling of the appropriate pearl monoclonal antibody of Buddhist nun;
(2) the appropriate pearl monoclonal antibody of the Buddhist nun of Alexa680 coupling and oral squamous cell carcinomas living cells are carried out to lucifuge and hatch rear washing;
(3) carrying out flow cytometer detection and Laser Scanning Confocal Microscope detects.
4. the method for a kind of stable fluorescence labeling oral squamous cell carcinomas living cells as claimed in claim 3, is characterized in that: the excitation wavelength that described flow cytometer detects is 633nm, transmitting filter disc 670LP.
5. the method for a kind of stable fluorescence labeling oral squamous cell carcinomas living cells as claimed in claim 3, is characterized in that: the excitation wavelength that described Laser Scanning Confocal Microscope detects is 633nm, transmitting filter disc 650LP.
6. the method for a kind of stable fluorescence labeling oral squamous cell carcinomas living cells as claimed in claim 1, is characterized in that: the appropriate pearl monoclonal antibody of the Buddhist nun fluorescent material used of described fluorescence coupling is quantum dot Qdot800.
7. the method for a kind of stable fluorescence labeling oral squamous cell carcinomas living cells as claimed in claim 6, is characterized in that: comprise the steps:
(1) by quantum dot Qdot800 and the coupling of the appropriate pearl monoclonal antibody of Buddhist nun;
(2) the appropriate pearl monoclonal antibody of the Buddhist nun of Qdot800 coupling and oral squamous cell carcinomas living cells are carried out to lucifuge and hatch rear washing;
(3) carrying out flow cytometer detection and Laser Scanning Confocal Microscope detects.
8. the method for a kind of stable fluorescence labeling oral squamous cell carcinomas living cells as claimed in claim 7, is characterized in that: the excitation wavelength that described flow cytometer detects is 407nm, transmitting filter disc 780/60nm.
9. the method for a kind of stable fluorescence labeling oral squamous cell carcinomas living cells as claimed in claim 7, is characterized in that: the excitation wavelength that described Laser Scanning Confocal Microscope detects is 488nm, transmitting filter disc 650LP.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310741811.2A CN103675262A (en) | 2013-12-27 | 2013-12-27 | Method of stable fluorescence labeling of living cells of oral squamous cell carcinoma |
| PCT/CN2014/082006 WO2015096456A1 (en) | 2013-12-27 | 2014-07-11 | Method for stably and fluorescently marking oral squamous cell carcinoma living cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310741811.2A CN103675262A (en) | 2013-12-27 | 2013-12-27 | Method of stable fluorescence labeling of living cells of oral squamous cell carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103675262A true CN103675262A (en) | 2014-03-26 |
Family
ID=50313448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310741811.2A Pending CN103675262A (en) | 2013-12-27 | 2013-12-27 | Method of stable fluorescence labeling of living cells of oral squamous cell carcinoma |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103675262A (en) |
| WO (1) | WO2015096456A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491881A (en) * | 2014-12-05 | 2015-04-08 | 北京肿瘤医院 | Fluorescence-coupled specific sentinel node photographic developer and preparation method thereof |
| WO2015096456A1 (en) * | 2013-12-27 | 2015-07-02 | 步荣发 | Method for stably and fluorescently marking oral squamous cell carcinoma living cells |
| CN108277196A (en) * | 2018-01-19 | 2018-07-13 | 武汉大学 | A kind of plasmid DNA transfection method of high-efficiency low-toxicity |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1268377A (en) * | 2000-03-15 | 2000-10-04 | 中国医学科学院医药生物技术研究所 | Antimatrix metalloprotease monovalent antibody Fab' medicine conjugate and its tumor-resisting action |
| CN101246169A (en) * | 2007-05-23 | 2008-08-20 | 四川大学 | Oral cavity squamous carcinoma diagnosis reagent, reagent kit and preventing and controlling medicament |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011060328A1 (en) * | 2009-11-13 | 2011-05-19 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| EP3296320A1 (en) * | 2012-03-08 | 2018-03-21 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| CN103675262A (en) * | 2013-12-27 | 2014-03-26 | 步荣发 | Method of stable fluorescence labeling of living cells of oral squamous cell carcinoma |
-
2013
- 2013-12-27 CN CN201310741811.2A patent/CN103675262A/en active Pending
-
2014
- 2014-07-11 WO PCT/CN2014/082006 patent/WO2015096456A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1268377A (en) * | 2000-03-15 | 2000-10-04 | 中国医学科学院医药生物技术研究所 | Antimatrix metalloprotease monovalent antibody Fab' medicine conjugate and its tumor-resisting action |
| CN101246169A (en) * | 2007-05-23 | 2008-08-20 | 四川大学 | Oral cavity squamous carcinoma diagnosis reagent, reagent kit and preventing and controlling medicament |
Non-Patent Citations (1)
| Title |
|---|
| 黄雪蕾: "舌鳞癌及前哨淋巴结近红外荧光活体成像的实验研究", 《中国博士学位论文全文数据库》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015096456A1 (en) * | 2013-12-27 | 2015-07-02 | 步荣发 | Method for stably and fluorescently marking oral squamous cell carcinoma living cells |
| CN104491881A (en) * | 2014-12-05 | 2015-04-08 | 北京肿瘤医院 | Fluorescence-coupled specific sentinel node photographic developer and preparation method thereof |
| CN108277196A (en) * | 2018-01-19 | 2018-07-13 | 武汉大学 | A kind of plasmid DNA transfection method of high-efficiency low-toxicity |
| CN108277196B (en) * | 2018-01-19 | 2020-10-13 | 武汉大学 | High-efficiency low-toxicity plasmid DNA transfection method |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015096456A1 (en) | 2015-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ruan et al. | DiR-labeled embryonic stem cells for targeted imaging of in vivo gastric cancer cells | |
| CN106053405A (en) | A super-resolution optical imaging method based on a single-molecule positioning process | |
| CN103675262A (en) | Method of stable fluorescence labeling of living cells of oral squamous cell carcinoma | |
| Ge et al. | Oxytocin facilitates the proliferation, migration and osteogenic differentiation of human periodontal stem cells in vitro | |
| CN102608102A (en) | Specific detection method of human breast cancer cells MCF-7 based on surface-enhanced Raman spectroscopy | |
| CN109142712B (en) | The preparation method of dendritic nano-tube array, the method for tumor cell and for capturing and the microfluidic devices of regulation cancer cell in situ | |
| CN103771390A (en) | Method for synthesizing carbon quantum dot by using biologic active enzyme auxiliary microwave method, carbon quantum dot prepared by using method, and application thereof | |
| CN108034636A (en) | Human breast cancer cell line and application | |
| Wang et al. | Supramolecular self-assembly of atomically precise silver nanoclusters with chiral peptide for temperature sensing and detection of arginine | |
| CN102621125A (en) | Cell probe complex for detecting human breast cancer cells MCF (Michigan cancer foundation)-7 based on Raman spectrum and method for preparing cell probe complex | |
| CN114303172A (en) | X, Y and Z-direction low power microscope objective pre-scan and high power microscope objective scan for imaging objects such as cells using a microscope | |
| CN105936892A (en) | Method for screening hybridoma cells with antigen specificity | |
| CN104685051A (en) | Method for culturing a subpopulation of circulating epithelial tumour cells from a body fluid | |
| CN101831403A (en) | Method for amplifying mesenchymal stem cells of human umbilical cord and placenta in vitro | |
| Gambini et al. | Differences in mitochondrial membrane potential identify distinct populations of human cardiac mesenchymal progenitor cells | |
| CN202583209U (en) | Optical excitation chemiluminiscence detection kit of pepsinogen I | |
| CN103060421B (en) | Autophagy monitoring method for fat cells | |
| CN107764789A (en) | Semisolid screening culture medium and its preparation method and application | |
| CN107227296A (en) | A kind of method of myelomonocyte separation, identification and induction differentiation | |
| CN102266561B (en) | Application of Wnt/beta-catenin signal channel inhibitor to preparation of medicament for promoting apoptosis | |
| CN100501402C (en) | Method of stably labelling liver cancer cell | |
| CN102796701A (en) | Method for amplifying human umbilical cord mesenchymal stem cells through in-vitro 3D stent-free suspension cultivation | |
| Hudiță et al. | Optimization of a flow cytometry method for the approach of liquid biopsy as a therapy modulation tool in patients with colorectal cancer | |
| WO2021012718A1 (en) | Pluripotent stem cells mdpscs for regeneration of dental pulp, separation culture method therefor, and use thereof | |
| CN109580951A (en) | The kit and its application method of multispecific antibody joint-detection early liver cancer marker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140326 |